All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
More information on our cookie policy.
BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Artificial intelligence
Coronavirus
Diagnosing and tracking COVID-19
Drugs to Watch 2020
The next pandemic
Premium reports
BioWorld Financings Reports
Disease Forecast Reports
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 13, 2021
Home
» First patient enrolled in phase IIa clinical study of ARQ-252 as potential treatment for vitiligo
First patient enrolled in phase IIa clinical study of ARQ-252 as potential treatment for vitiligo
March 22, 2021
No Comments
Article reprints
Source:
https://science.bioworld.com/ddn/article.do?id=177074
BioWorld Science
Related Articles
First patients enrolled in phase I study of PTP-001 as treatment of knee OA
First patient dosed in phase I study of TH-1902 as treatment of sortilin-positive solid tumors
